Pelvic Insufficiency Fractures and Bone Pain after Radiation Therapy for Anal Cancer: Relation to Pelvic Bone Dose-Volume Parameters.
| Autor: | Kronborg CJ; Danish Centre for Particle Therapy, Aarhus, Denmark., Pedersen BG; Department of Radiology, Aarhus University Hospital, Aarhus, Denmark., Klemmensen J; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Lefévre AC; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Wind KL; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Spindler KG; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Advances in radiation oncology [Adv Radiat Oncol] 2022 Oct 20; Vol. 8 (1), pp. 101110. Date of Electronic Publication: 2022 Oct 20 (Print Publication: 2023). |
| DOI: | 10.1016/j.adro.2022.101110 |
| Abstrakt: | Purpose: Chemoradiation therapy is the primary treatment for anal cancer. Radiation therapy (RT) can weaken the pelvic bone structure, but the risk of pelvic insufficiency fractures (PIFs) and derived pain in anal cancer is not yet established. We determined the frequency of symptomatic PIFs after RT for anal cancer and related this to radiation dose to specific pelvic bone substructures. Methods and Materials: In a prospective setting, patients treated with RT for anal cancer had magnetic resonance imaging 1 year after RT. PIFs were mapped to 17 different bone sites, and we constructed a guideline for detailed delineation of pelvic bone substructures. Patients were interviewed regarding pain and scored according to Common Terminology Criteria for Adverse Effects. Dose-volume relationships for specific pelvic bone substructures and PIFs were determined for V20 to V40 Gy mean and maximum doses. Results: Twenty-seven patients were included, and 51.9% had PIFs primarily located in the alae of the sacral bone. Patients with PIFs had significantly more pelvic pain (86% vs 23%, P = .001) and 43% had grade 2 bone pain. Dose-volume parameters for sacral bone and sacral alae were significantly higher in patients with PIFs ( P < .05). V30 Gy (%) for sacral bone and alae implied an area under the curve of 0.764 and 0.758, respectively, in receiver operating characteristic analyses. Conclusions: We observed a high risk of PIFs in patients treated with RT for anal cancer 1 year after treatment. A significant proportion had pain in the sites where PIFs were most frequently found. Radiation dose to pelvic bone substructures revealed relation to risk of PIFs and can be used for plan optimization in future clinical trials. (© 2022 The Author(s).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|